A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
While 95% of patients with retinoblastoma can be cured nowadays, treatment of relapse remains
challenging, ending often in enucleation and/or radiotherapy. In the last 10 years, new
treatment modalities have been developed to give the chance of cure also in relapse, avoiding
enucleation which results in esthetic sequelae and orbital growth problems, and radiotherapy
which significantly increases the risk of secondary cancers in hereditary retinoblastoma. The
current protocol aims at covering all types of relapses in retinoblastoma, with treatments
adapted to the site of relapse, at harmonizing the new eye- and vision-preserving treatment
procedures, and evaluating their efficacy and toxicity.